Treatment

ALZ-801 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2, SINGLE-ARM STUDY OF THE BIOMARKER EFFECTS OF ALZ-801 IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE WHO ARE CARRIERS OF THE ε4 VARIANT OF THE APOLIPOPROTEIN E GENE (APOE4/4 or APOE3/4)
This study is looking at a new drug called ALZ-801 for people with early Alzheimer's disease who have specific genetic markers. It aims to see how the drug affects certain markers in the body and brain over two years, with options for longer follow-up.
For: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4 · APOE3/4) and at the Early stage of disease · ages 50-80 years
Czechia · Netherlands